Skip to main content
. Author manuscript; available in PMC: 2012 Jun 18.
Published in final edited form as: Basic Res Cardiol. 2011 May 10;106(5):773–785. doi: 10.1007/s00395-011-0189-5

Fig. 1.

Fig. 1

GSK-3β signaling components in vSMC. a Immunohistochemical staining and b western blot analysis of total GSK-3β and pGSK-3β in rat vSMC. c Pharmacological inhibition of GSK-3β activity with increasing concentrations of SB-216763 after 24 h treatment. d Ectopic expression of constitutively active mutant GSK-3β S9A (Mut.GSK-3β) in vSMC using anti-GFP after 72 h and e Western blot analysis of GSK-3β levels following ectopic expression of GSK-3β S9A (Mut.GSK-3β) with anti-HA and siRNA knockdown with anti-GSK-3β after 72 h. Data are representative of three independent experiments with similar results